ANXA5 M2 Haplotyping in IVF Patients and Embryos
Condition(s) studied
Investigational drug(s) / intervention(s)
M2 Test: DNA will be extracted from saliva samples obtained from participants. Genetic testing will be performed to screen for the M2 mutation and determine the carrier status of each patient and partner.
Study summary
This study aims to characterize the association between history of pregnancy complications and M2 carrier status in IVF patients and the utility of M2 haplotype preimplantation genetic testing (PGT) in embryos produced by carrier couples. Participants in this study will be screened for the M2 variant. History of pregnancy complications and miscarriages will be studied in order to determine potential associations with M2 carrier-ship.
Eligibility
Primary outcome measure(s)
- M2 Haplotype frequency — 1 month
Frequency of carriers of the M2 haplotype attending an IVF center for infertility treatment.
Trial sites (1)
| Facility | City | Region | Status |
|---|---|---|---|
| Genomic Prediction Clinical Laboratory | North Brunswick | New Jersey |
More Genomic Prediction Inc. trials in the USA
Other trials for the same condition
This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.
View NCT04544462 on ClinicalTrials.gov ↗ ← All trials in the USA